logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (4)
  • CSV
  • BibTeX
  • EndNote
  • All Results (4)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study

Gelé T, Atwine D, Baudin E, Muyindike W, Mworozi K,  et al.
2025-08-29 • Journal of Antimicrobial Chemotherapy
2025-08-29 • Journal of Antimicrobial Chemotherapy

BACKGROUND

Increasing rifampicin dosing is considered a potent strategy for shortening TB treatment ...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Four-month high-dose rifampicin regimens for pulmonary tuberculosis

Jindani A, Atwine D, Grint D, Bah B, Adams J,  et al.
2023-09-01 • NEJM Evidence
2023-09-01 • NEJM Evidence
BACKGROUND
Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid a...

A randomised phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis

Jindani A, Borgulya G, de Patino IW, Gonzales T, de Fernandes RA,  et al.
2016-06-01 • International Journal of Tuberculosis and Lung Disease
2016-06-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Randomised Phase IIB clinical trial.

OBJECTIVES
To assess whether increasing the dose of rifampicin (RMP) from 10 mg/kg to 15 or 20 mg/kg results in an increase ...

Predictors of delayed culture conversion among Ugandan patients

Atwine D, Orikiriza P, Taremwa IM, Ayebare A, Logoose S,  et al.
2017-04-24 • BMC Infectious Diseases
2017-04-24 • BMC Infectious Diseases
BACKGROUND
Estimates of month-2 culture conversion, a proxy indicator of tuberculosis (TB) treatment efficacy in phase-2 trials can vary by culture-type and geographically with lower...